Table 2.
Distribution of treatment regimens in the first episodes of 50 TB cases with a recurrence
| Treatment group | Total in group | Intensive phase short | Intensive phase adequate | Duration of treatment short | Duration of treatment adequate |
|---|---|---|---|---|---|
| Standard treatment Aa | 15 | NA | 15 | 1 | 14 |
| Standard treatment Bb | 4 | NA | 4 | 2 | 2 |
| Standard treatment with short intensive phase Cc | 3 | 3 | NA | 2 | 1 |
| Standard treatment Dd | 14 | 0 | 14 | 1 | 13 |
| Other probably effective combination of anti-TB drugse | 6 | NA | NA | 1 | 5 |
| Other probably ineffective combination of anti-TB drugsf | 6 | NA | NA | NA | NA |
| Not evaluated | 2 | – | – | – | – |
NA not applicable, H isoniazid, R Rifampicin, Z pyrazinamide, E ethambutol
a HRZ in intensive phase, HR in continuation phase, adequate duration of treatment ≥ 5.5 months
b HRE in intensive phase, HR in continuation phase, adequate duration of treatment ≥ 8 months
c Short intensive phase <54 days in standard treatment A or B
d ≥ 4 anti-TB drugs, including HRZ (adequate duration of treatment ≥ 5.5 months) or HRE (adequate duration of treatment ≥ 8 months)
e Non-standard combinations guided by drug resistance or due to adverse effects, the adequacy of treatment duration assessed by the study group
f Drug resistance ignored or inappropriate dosing